Jiangxi Qingfeng Pharma 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   1 Trial   1 News 


«12
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Clinical, Retrospective data, Journal:  Bayesian network Meta-analysis of traditional Chinese medicine injections combined with antiviral western medicine in treatment of influenza (Pubmed Central) -  Sep 2, 2021   
    A total of 49 literatures about 5 061 cases were included finally, involving six traditional Chinese medicine injections, namely Reduning Injection, Xiyanping Injection, Tanreqing Injection, Yanhuning Injection, Qingkailing Injection and Shuanghuanglian Injection...Because of the small quantity and low quality of included studies, the results of this study shall be regarded cautiously and comprehensively. In the future, multi-center, large-sample and clinical randomized controlled trials shall be conducted to verify the results.
  • ||||||||||  Xiyanping / Jiangxi Qingfeng Pharma
    Retrospective data, Journal:  Efficacy of Chinese Herbal Injections for Elderly Patients With pneumonia-A Bayesian Network Meta-analysis of Randomized Control Trials. (Pubmed Central) -  Jun 8, 2021   
    We ultimately identified 34 eligible randomized controlled trials that involved 3,111 elderly participants and investigated 4 CHIs combined with Western medicine (WM) (Xiyanping injection [XYP]+WM, Yanhuning injection [YHN]+WM, Tanreqing injection [TRQ]+WM, Reduning injection [RDN]+WM), contributing 34 direct comparisons between CHIs...Our findings were based on very limited evidence and thus should be interpreted with caution. The application of the findings requires further research.
  • ||||||||||  SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
    Enrollment open, Monotherapy, Metastases:  Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (clinicaltrials.gov) -  May 11, 2021   
    P2,  N=104, Recruiting, 
    The application of the findings requires further research. Not yet recruiting --> Recruiting
  • ||||||||||  Xiyanping / Qingfeng, CBT-1 (tetrandrine) / CBA Pharma
    Review, Journal:  Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts. (Pubmed Central) -  Jan 26, 2021   
    The use of Chinese herbal medicines that are capable of inhibiting SARS-Cov-2 infection may help to address this immediate unmet clinical need and may be attractive to other countries that are also seeking new options for effective COVID-19 treatment. Our analyses suggest that countries outside of China should also consider protocols involving Chinese herbal medicines combat this fast-spreading viral infection.
  • ||||||||||  Xiyanping / Qingfeng
    Retrospective data, Review, Journal:  Efficacy and safety of Xiyanping for COVID-2019: A protocol for systematic review and meta-analysis. (Pubmed Central) -  Nov 26, 2020   
    Our analyses suggest that countries outside of China should also consider protocols involving Chinese herbal medicines combat this fast-spreading viral infection. Our study aims to systematically present the clinical evidence of Xiyanping in the treatment of COVID-19, which will be of guiding significance for further research and clinical practice.
  • ||||||||||  Xiyanping / Qingfeng
    Clinical, Journal:  Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations. (Pubmed Central) -  Nov 11, 2020   
    Differences in the type of study, interventions, and registration sources of the studies led to significant differences in certain parameters of the COVID-19 clinical trials. The statistics of high-frequency drugs and the progress of vaccine trials may provide an informative reference for the prevention and control of COVID-19.
  • ||||||||||  Xiyanping / Qingfeng
    Review, Journal:  Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China. (Pubmed Central) -  Aug 28, 2020   
    This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP)...In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal. Knowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic.
  • ||||||||||  SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
    New P1/2 trial, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases:  SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation (clinicaltrials.gov) -  Jul 26, 2020   
    P1/2,  N=90, Not yet recruiting, 
  • ||||||||||  Trial initiation date:  Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia (clinicaltrials.gov) -  May 19, 2020   
    P=N/A,  N=426, Not yet recruiting, 
    Due to the small sample size, more studies are required to verify the strength of evidence. Initiation date: Feb 2020 --> May 2020
  • ||||||||||  Xiyanping / Qingfeng
    Clinical, Journal:  Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019 (Pubmed Central) -  Apr 18, 2020   
    The experimental interventions included Chinese patent medicine(Lianhua Qingwen Capsules/Granules, Huoxiang Zhengqi Dropping Pills/Oral Liquid, Babao Dan, Gubiao Jiedu Ling, Jinhao Jiere Granules, Compound Yu-xingcao Mixture, Jinye Baidu Granules, Shufeng Jiedu Capsuless, Shuanghuanglian Oral Liquid, Tanreqing Injection, Xuebijing Injection, Reduning Injection, Xiyanping Injection), Chinese medicinal decoction and taichi...There was a quick response of clinical research on the prevention and treatment of COVID-19 with TCM, with the current registered protocols covers the whole process of disease prevention, treatment and rehabilitation. However, issues need to be concerned, including unclear definition of patient's condition, unclear research objectives, unclear intervention process and inappropriate outcomes, etc. In addition, researchers should consider the actual difficulties and workload of doctors in epidemic response environment, and make effort to optimize the process and improve the operability of research protocols under the principle of medical ethics.
  • ||||||||||  SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
    New P1 trial, BRCA Biomarker, PARP Biomarker:  A Study of SC10914 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Dec 29, 2017   
    P1,  N=72, Recruiting,